November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
10 citations
,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
12 citations
,
November 2023 in “Skin Appendage Disorders” JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.
2 citations
,
November 2007 in “Clinics in dermatology” Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
3 citations
,
June 2025 in “Archives of Dermatological Research” Stopping TNFα inhibitors can help children regrow hair lost due to the medication.
2 citations
,
May 2025 in “Archives of Dermatological Research” JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
96 citations
,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
15 citations
,
July 2020 in “Applied Sciences” PRS injections can improve knee function and reduce pain for up to a year.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.
January 2015 in “Annals of dermatology/Annals of Dermatology” Using travoprost for glaucoma may cause extra hair growth and darker skin around the eyes, but these effects can reverse after stopping the drug.
2 citations
,
January 2020 in “Skin Appendage Disorders” Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
6 citations
,
January 2012 in “Journal of Biomedicine and Biotechnology” Ustekinumab might work for severe psoriasis, but more research is needed to be sure.
April 2017 in “Journal of Investigative Dermatology” SM04755 may be an effective topical treatment for psoriasis.
Intralesional methotrexate effectively treats alopecia areata by reducing TNF-α levels, leading to hair regrowth.
14 citations
,
January 2017 in “Dermatology Online Journal” Adalimumab can cause hair loss and scalp issues in some psoriasis patients.
October 2025 in “Cell Death and Disease” CD271 is crucial for maintaining healthy skin and preventing inflammation.
May 2024 in “International journal of medicine and psychology.” Transcranial electrical stimulation with bisphosphonates helps maintain bone collagen better than bisphosphonates alone.
14 citations
,
May 2022 in “International Journal of Molecular Sciences” Platelet-rich plasma improves bladder function and reduces overactivity in ketamine-induced bladder issues.
November 2023 in “SKIN The Journal of Cutaneous Medicine” 4 citations
,
August 2024 in “Skin Research and Technology” The study was retracted.
December 2021 in “Intisari Sains Medis” Botulinum toxin injections improved hair thinning in a woman with hair loss.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.